Podcast

Dr. Giulia Lane discusses urethral stricture disease in women

Author(s):

Urology Times staff

On the latest episode of the Speaking of Urology podcast, Dr. Giulia Lane discusses her recent study evaluating treatment of urethral stricture disease in women.

This episode’s guest is Giulia I. Lane, MD, MS. She discusses the recent Neurourology and Urodynamics article, Treatment of urethral stricture disease in women: A multi‐institutional collaborative project from the SUFU research network, for which she served as a study author. Lane is a fellow in female pelvic medicine and reconstructive surgery at the University of Michigan, Ann Arbor.

Related Videos
Anna Myers, CNP, answers a question during a Zoom video interview
Anna Myers, CNP, discusses her approach to preventing UTIs
Vanita Gaglani, RPT, answers a question during a video interview
Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
Diet and interstitial cystitis: A urologist’s view
Diet and interstitial cystitis: A urologist’s view
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
J. Quentin Clemens, MD, on tailoring interstitial cystitis treatment
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Top 10 Urology Times videos of 2024
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Expert: Catheter reprocessing device has potential to be “game changer”
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Dr. A. Lenore Ackerman on sulopenem and the UTI treatment landscape
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
Expert discusses sulopenem for uncomplicated UTI
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Dr. A. Lenore Ackerman on antibiotic stewardship in managing UTIs
Christian Moro, PhD, BSc, BEd, MBus, SFHEA, answers a question during a Zoom video interview
Dr. Christian Moro on education regarding UTI prevention
Related Content
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
May 28th 2025

Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy

Hannah Clarke
These data are intended to support a new drug application to the FDA in the second half of 2025.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Novel drug delivery approach shows promise for UTI
March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke
The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux
January 14th 2025

FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux

Hannah Clarke
In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.
In-depth study of microbiomes may lead to better UTI care for patients with spina bifida
January 6th 2025

In-depth study of microbiomes may lead to better UTI care for patients with spina bifida

Brendan T. Frainey, MD
"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.
© 2025 MJH Life Sciences

All rights reserved.